Meta Navigation

Header Image

Geistlich Pharma has won second prize in the “Business Transformation” category of the “SAP Quality Excellence Awards”.

Corporate News

2014 · 2013 ·
  • Between 19 and 27 September, important congresses on regenerative dental medicine were held in the three metropolises of San Francisco, Shanghai and Rome. Geistlich managed the balancing act between three continents and between scientificity and practical relevance.

  • According to a court settlement of 12 May 2014, the South Korean company Osstem must refrain from any distribution of dental products under the name B-Oss and destroy all existing products bearing this name. The name and the packaging of this product were similar to that of the long-standing market leader Geistlich Bio-Oss®.

  • Geistlich Pharma wins the 2014 prize for innovation from the Chamber of Industry and Commerce of Central Switzerland (IHZ). The IHZ rated the products Geistlich Mucograft® and Geistlich Mucograft® Seal as an outstanding achievement.

  • At its meeting on 26 August 2014, the Board of Directors of Geistlich Pharma AG reconstituted itself. Dr Andreas Geistlich is the new President of the Board of Directors.

  • Colleagues and management mourn the passing of Dr. Peter Geistlich; over many years he decisively shaped the development of the family company which is over 160 years old, enabling it to enter regenerative medicine. The obituary recalls and honours Peter Geistlich, scientist, entrepreneur and unique human being. 

  • The new website of Geistlich Pharma AG has been live since today. With the re-launch, the information content has been tailored even more specifically to the information requirements of specialist clinic personnel and their patients. In addition to product information, therapy concepts with case studies and easy-to-understand video material are also available. Furthermore, the website has a fresher design and a more user-friendly web architecture.

  • In 2013, the global economy was once again characterised by uncertainty and reticence. In this difficult environment, Geistlich Pharma AG again asserted itself very well as a Swiss SME. The company posted solid growth and strengthened or even expanded its position in virtually all its markets. Once again, the balanced geographical mix, an attractive product pipeline and the operational strength of the company were contributing factors.

  • Innovation is an everyday occurrence at Geistlich. The film “The Art of Innovation” is designed to give a better idea of what this everyday life looks like and to make it accessible to the public at large.

  • Following on from the bone replacement material Geistlich Bio-Oss®, the Japanese authorities have now also granted a licence to Geistlich Bio-Gide®. The sales launch of the collagen membrane for bone regeneration is to take place shortly.

  • With immediate effect two new laws in the US and France will regulate collaboration between medicine and industry. The goal of both laws is to ensure greater transparency in future towards the general public and thus prevent conflicts of interest. All payments from manufacturers to the medical profession will be published on the Internet.

Dr. Mirjam Kessler
Director Corporate Communications
Flickr Photo Stream

For printable images, please send an e-mail to

YouTube Geistlich Channel

Geistlich Pharma AG - Channel­